Call +44 (0)1904 798634 or +44 (0)7550 079918

Leading provider of life science market reports and research services

SYSTEMIC SCLEROSIS (SCLERODERMA) – OPPORTUNITY ANALYSIS AND FORECAST TO 2024

Be the first to review this product

OpportunityAnalyzer: Systemic Sclerosis (Scleroderma) – Opportunity Analysis and Forecast to 2024
You can choose to pay by purchase order during checkout

Availability: In stock

$10,995.00

* Required Fields

You can choose to pay by purchase order during checkout
GlobalData.

Digital downloads direct to your inbox within 24 hours.

First class customer service from our team of experts.

Pay by credit card or request an invoice

Product Description

Details

Systemic sclerosis (SSc) is a complex autoimmune disease that affects the skin and multiple internal organs. Common manifestations of SSc that are included in this report are skin fibrosis, lung fibrosis, and digital vasculopathy (including Raynaud’s phenomenon [RP], and digital ulcers [DUs]). Although the etiology is not completely understood, it is believed to be caused by environmental triggers within genetically susceptible individuals. The clinical presentation of the disease varies between patients and treatment is mostly directed at managing its complications within each internal organ, as there are no systemic or disease-modifying treatments that significantly alter the course of the disease. Most drugs used to treat SSc are off-label and include immunosuppressive agents for skin and lung fibrosis and vasodilatory agents to treat digital vasculopathy. GlobalData expects the launch of three drugs during the 2014 to 2024 forecast period, including two biologic agents for fibrosis (Genentech/Roche’s Actemra and BMS’ Orencia) and Allergan’s Botox to treat digital vasculopathy.

Scope

  • Overview of SSc, including etiology, pathophysiology, symptoms, and treatment recommendations.
  • Annualized SSc market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the SSc market.
  • Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically Roche/Genentech’s Actemra, Roche/Genentech’s Rituxan, BMS’s Orencia, and Allergan’s Botox.
  • Analysis of the current and future market competition in the global SSc market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

  • With three drug launches, two of which are biologics, which products are forecast to generate the highest sales over 2014-2024? How are product launches expected to affect immunosuppressants?
  • What do SSc specialists across the 7MM think about the evolving treatment landscape? How will the results from the Scleroderma Lung Study II and update to the 2009 EULAR guidelines affect the management of SSc?
  • What corporate strategies have been employed for recent product launches? What opportunities remain for new entrants?
  • According to KOLs, what are the most important unmet needs in SSc? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2024?
  • How do payers view the unmet needs for SSc and how do reimbursement practices affect drug availability?

Additional Information

Additional Information

Publisher name GlobalData.
Format PDF
Page count 279
Publication date 29 Dec 2015
Table of contents

Report sample

Reviews

Write Your Own Review

Only registered users can write reviews. Please, log in or register

Product Tags

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.